LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, -, -
CLOU064M12301
Phase 3 small_molecule active
Quick answer
LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, -, - for Chronic Inducible Urticaria (CINDU) is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Chronic Inducible Urticaria (CINDU)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active